STOCK TITAN

LivaNova PLC (LIVN) 10-K Filings

LIVN NASDAQ

Here are the 10-K annual reports from LivaNova PLC (LIVN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow LIVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIVN filings page.

Rhea-AI Summary

LivaNova PLC is a London‑based global medical technology company focused on two segments: Cardiopulmonary and Neuromodulation. It sells heart‑lung machines, oxygenators, perfusion systems, cannulae, and neuromodulation devices such as its VNS Therapy System, serving patients with drug‑resistant epilepsy, difficult‑to‑treat depression, and obstructive sleep apnea.

The company invests in R&D, including AI and software, and runs major clinical programs like the RECOVER depression study and the OSPREY trial for its aura6000 sleep apnea system. For 2025, 53% of net revenue came from the U.S., 19% from Europe, and 28% from the rest of the world. It reports extensive global regulatory, cybersecurity, trade, environmental, and compliance risks and highlights exposure to sanctions regimes through limited sales into Iran and other sanctioned markets.

As of December 31, 2025, LivaNova employed about 3,300 people in 34 countries and emphasizes culture, leadership development, and diversity initiatives as part of its human capital strategy.